Canton Strategic Holdings (CNTN) EBT (2021 - 2026)
Canton Strategic Holdings' (CNTN) quarterly EBT came in at -$51.6 million in Q1 2026, down 1928.7% YoY from $2.8 million in Q1 2025, and down 279.3% on a QoQ basis from -$13.6 million in Q4 2025.
Canton Strategic Holdings (CNTN) EBT (2021 - 2026) Analysis & Trends
Canton Strategic Holdings (CNTN) has 6 years of EBT data on file, last reported at -$51.6 million in Q1 2026.
- Quarterly EBT fell 1928.7% year-over-year to -$51.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$69.1 million (down 455.17% YoY) and the FY2025 annual result came in at -$42.1 million, down 245.18% from the prior year.
- EBT eased to -$51.6 million in Q1 2026, from -$13.6 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$197435.0 in Q4 2022 to a low of -$51.6 million in Q1 2026.
- A 5-year average of -$5.9 million and a median of -$2.3 million in 2023 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT surged 45.09% — and 2026, when it slumped 1928.7%.
- Tracing CNTN's EBT over 5 years: stood at -$197435.0 in 2022, then plunged by 1152.96% to -$2.5 million in 2023, then slumped by 53.08% to -$3.8 million in 2024, then sank by 259.0% to -$13.6 million in 2025, then tumbled by 279.3% to -$51.6 million in 2026.
- The last three EBT figures came in at -$51.6 million (Q1 2026), -$13.6 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Canton Strategic Holdings | 419.57 Mn | 419.57 Mn | - | -51.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.56 Mn |
| Dec 31, 2025 | -13.59 Mn |
| Sep 30, 2025 | -2.10 Mn |
| Jun 30, 2025 | -1.86 Mn |
| Mar 31, 2025 | -2.54 Mn |
| Dec 31, 2024 | -3.79 Mn |
| Sep 30, 2024 | -3.80 Mn |
| Jun 30, 2024 | -2.33 Mn |
| Mar 31, 2024 | -2.26 Mn |
| Dec 31, 2023 | -2.47 Mn |
| Sep 30, 2023 | -1.82 Mn |
| Jun 30, 2023 | -2.34 Mn |
| Mar 31, 2023 | -2.69 Mn |
| Dec 31, 2022 | -197,435.00 |
| Sep 30, 2022 | -2.12 Mn |
| Jun 30, 2022 | -1.64 Mn |
| Mar 31, 2022 | -2.95 Mn |
| Dec 31, 2021 | -359,593.00 |
| Sep 30, 2021 | -777,113.00 |
| Jun 30, 2021 | -1.29 Mn |